Literature DB >> 31003063

A comparison of potential psychiatric drug interactions from six drug interaction database programs.

Scott Monteith1, Tasha Glenn2.   

Abstract

Harmful drug-drug interactions (DDI) frequently include psychiatric drugs. Drug interaction database programs are viewed as a primary tool to alert physicians of potential DDI, but may provide different results as there is no standard to define DDI. This study compared the category of potential DDI provided by 6 commercial drug interaction database programs (3 subscription, 3 open access) for 100 drug interaction pairs. The pairs involved 94 different drugs; 67 included a psychiatric and non-psychiatric drug, and 33 included two psychiatric drugs. The category assigned to the potential DDI by the 6 programs was compared using percent agreement and Fleiss' kappa interrater reliability measure. The overall percent agreement for the category of potential DDI for the 100 drug interaction pairs was 66%. The Fleiss kappa overall interrater agreement was fair. The kappa agreement was substantial for interaction pairs with any severe category rating, and fair for interaction pairs with any major category rating. The category of potential DDI for drug interaction pairs including psychiatric drugs often differs among drug interaction database programs. Modern technology allows easy access to several interaction database programs. When assistance from a drug interaction database program is needed, the physician should check more than one program.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical decision support systems; Drug interaction checker; Drug interaction screening; Drug interaction software; Drug-drug interactions; Psychiatric drugs

Year:  2019        PMID: 31003063     DOI: 10.1016/j.psychres.2019.03.041

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review.

Authors:  Beatriz Oda Plasencia-García; Gonzalo Rodríguez-Menéndez; María Isabel Rico-Rangel; Ana Rubio-García; Jaime Torelló-Iserte; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2021-01-07       Impact factor: 4.530

2.  Assessing Consistency of Drug-Drug Interaction-Related Information Across Various Drug Information Resources.

Authors:  Atiqulla Shariff; Sathvik Belagodu Sridhar; Neelu Farhath Abdullah Basha; Shamma Sulaiman Hasan Bin Taleth Alshemeil; Noora Adel Ahmed Aljallaf Alzaabi
Journal:  Cureus       Date:  2021-03-08

3.  Potential Psychotropic and COVID-19 Drug Interactions: A Comparison of Integrated Evidence From Six Database Programs.

Authors:  Javedh Shareef; Sathvik Belagodu Sridhar; Sabin Thomas; Atiqulla Shariff; Sriharsha Chalasani
Journal:  Cureus       Date:  2021-12-10

4.  Drug-Related Problems and Polypharmacy in Nursing Home Residents: A Cross-Sectional Study.

Authors:  Raquel Díez; Raquel Cadenas; Julen Susperregui; Ana M Sahagún; Nélida Fernández; Juan J García; Matilde Sierra; Cristina López
Journal:  Int J Environ Res Public Health       Date:  2022-04-04       Impact factor: 3.390

5.  Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases.

Authors:  Michael Hecker; Niklas Frahm; Paula Bachmann; Jane Louisa Debus; Marie-Celine Haker; Pegah Mashhadiakbar; Silvan Elias Langhorst; Julia Baldt; Barbara Streckenbach; Felicita Heidler; Uwe Klaus Zettl
Journal:  Front Pharmacol       Date:  2022-08-05       Impact factor: 5.988

6.  Evaluation of drug information resources for interactions between therapeutic drugs and drugs of abuse.

Authors:  Robert D Beckett; Jennifer R Martin; Curtis D Stump; Megan A Dyer
Journal:  J Med Libr Assoc       Date:  2020-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.